Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

0.8431 -0.0220 (-2.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Difference
Context Therapeutics Inc. (NASDAQ: CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors by harnessing novel and innovative treatment targets such as Claudin 6... 
Via Benzinga
Context Therapeutics to Participate in Two April 2023 Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning! 
Via InvestorPlace
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET 
From Context Therapeutics Inc.
Via GlobeNewswire
$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Context Therapeutics And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 370 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Insiders Buying AmeriServ Financial And 2 Other Penny Stocks
The Dow Jones dropped by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Higher By 42%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed over 1% higher on Tuesday, led by upbeat corporate earnings and expectations that the Federal Reserve will slow down its rate hike pace as the centr 
Via Benzinga
Dow Surges Over 200 Points; Pfizer Issues Weak Forecast
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.63% to 33,931.13 while the NASDAQ rose 1.20% to 11,529.99. The S&P... 
Via Benzinga
Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies
Context Therapeutics Inc (NASDAQ: CNTX) shares are trading higher by 60.32% to $1.10 Tuesday afternoon after the company announced its clinical trial collaborator, Stemline Therapeutics, received... 
Via Benzinga
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Dow Turns Higher; Nasdaq Jumps 100 Points
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 0.19% to 33,781.23 while the NASDAQ rose 0.90% to 11,496.13. The S&P... 
Via Benzinga
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying
The Nasdaq dropped more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
From Context Therapeutics Inc.
Via GlobeNewswire
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split. 
Via Benzinga
Why Context Therapeutics Stock Is Falling 25% Today
Context Therapeutics Inc (NASDAQ: CNTX) shares are trading lower by 26.62% to $1.02 during Thursday's session after the company reported preliminary Phase 2 data for ONA-XR metastatic breast cancer.... 
Via Benzinga
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented 
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug
Context Therapeutics Inc. (NASDAQ: CNTX) and Integral Molecular are teaming up to develop an anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for cancer therapy.  
Via Benzinga
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.